Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 19/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | FRK | P42685 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.49 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6701760 | 0.93 | MAPK11 (0.87) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| Fumaric Acid SCHEMBL6701770 | 0.93 | MAPK11 (0.87) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| SCHEMBL14411732 | 0.85 | MAPK11 (0.75) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| SCHEMBL6210836 | 0.85 | MAPK11 (0.77) | MAPK11MAPK14 | |
| SCHEMBL6210833 | 0.85 | MAPK11 (0.77) | MAPK11MAPK14 | |
| SCHEMBL6701766 | 0.84 | MAPK11 (0.72) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| SCHEMBL14411731 | 0.84 | MAPK11 (0.74) | MAPK11MAPK14MAP4K4EGFRPRKACA | |
| SCHEMBL185300 | 0.83 | MAPK11 (1.00) | MAPK11MAPK14 | |
| SCHEMBL29798827 | 0.83 | MAPK11 (1.00) | MAPK11MAPK14 | |
| SCHEMBL14519351 | 0.81 | MAPK11 (1.00) | MAPK11MAPK14MAP4K4EGFRPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511743-A1 | PYRAZOLE-DERIVATIVES AS P38 KINASE INHIBITORS | Pharmacia Corporation (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040082551-A1 | Novel pyrazoles and their use as p38 kinase inhibitors | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
| WO-2003104223-A1 | PYRAZOLE-DERIVATIVES AS P38 KINASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082551-A1 | Novel pyrazoles and their use as p38 kinase inhibitors | MAPK1, MAPK3, MAP3K1 | MAPK11 42/4885MAPK14 31/4885MAP4K4 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.